#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL

Self-management of rheum disease is ripe for apps, gamification. How well does it work though? This app (Axia) in axSpA was basically as good as a biologic. Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that #EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89

#RA #recommendations #update Some recommendations were merged For sure some regions will consider #Combination #csDMARDs or Switch to another 👇🤔 #sulfasalazine #leflunomide Depends on access, pt preference, disease activity/severity #EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV

🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. @RheumNow #EULAR2025 #LB0004

Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM

Tapering in RA? In SORAIRO (n=149), pts in remission on ozoralizumab+MTX: 🧪 49% became MTX-free ⏱ 80% spaced OZR to q8w CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8 LB0006 @RheumNow #EULAR2025

#EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB

Leaky pipeline in rheumatology: In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men. Top reasons? 🚫 Unfair promotion 🚫 Poor communication 🚫 No career path Workplace equity still lags. POS0407 @RheumNow #EULAR2025

RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. @RheumNow #EULAR2025 #LB0005

Nerandomilast: the new & improved nintedanib. Does it work for our rheum pts? Autoimmune subgroup of FIBRONEER-ILD (NEJM last month) - mortality benefit vs placebo (this is new) - well tolerated (minimal increase in diarrhoea vs placebo) One to watch #EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW